You are here:

calcium polystyrene sulphonate powder for oral/rectal suspension (Sorbisterit®)

Advice

following an abbreviated submission:

calcium polystyrene sulphonate powder (Sorbisterit®) is accepted for use within NHS Scotland.

Indication under review: treatment of hyperkalaemia, in patients with acute and chronic renal insufficiency, including patients undergoing dialysis treatment.

Sorbisterit® provides an alternative to the existing proprietary product at a lower cost. The dose of Sorbisterit® and the existing proprietary product differ as the strength of the active ingredient varies slightly.
 

Drug Details

Drug Name: calcium polystyrene sulphonate powder for oral/rectal suspension (Sorbisterit®)
SMC Drug ID: 890/13
Manufacturer: Stanningly Pharma Limited
Indication: For treatment of hyperkalaemia, in patients with acute and chronic renal insufficiency, including patients undergoing dialysis treatment.
BNF Category:
Sub Category: 9.2 Fluids and electrolytes
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 12 August 2013

Back